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0022-2836/$ - see front matter © 2008 ETankyrases are recently discovered proteins implicated in many important
functions in the cell including telomere homeostasis and mitosis. Tankyrase
modulates the activity of target proteins through poly(ADP-ribosyl)ation,
and here we report the structure of the catalytic poly(ADP-ribose) poly-
merase (PARP) domain of human tankyrase 1. This is the first structure of a
PARP domain from the tankyrase subfamily. The present structure reveals
that tankyrases contain a short zinc-binding motif, which has not been pre-
dicted. Tankyrase activity contributes to telomere elongation observed in
various cancer cells and tankyrase inhibition has been suggested as a poten-
tial route for cancer therapy. In comparison with other PARPs, significant
structural differences are observed in the regions lining the substrate-
binding site of tankyrase 1. These findings will be of great value to facilitate
structure-based design of selective PARP inhibitors, in general, and tanky-
rase inhibitors, in particular.
© 2008 Elsevier Ltd. All rights reserved.Edited by G. Schulz Keywords: tankyrase; poly(ADP-ribose) polymerase; inhibitor design; zincIntroduction
Tankyrase (TRF1-interacting ankyrin-related ADP-
ribose polymerase, TNKS)was first identified in 19981
and found to interact with telomeric repeat binding
factor (TRF1), a protein that binds to and protects
telomeric DNA. The human genome encodes two
tankyrases, TNKS-1 and TNKS-2, which have highresses:
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lsevier Ltd. All rights reservesequence identity (Fig. 1). Tankyrases belong to the
poly(ADP-ribose) polymerase (PARP) family of pro-
teins that all share a catalytic PARP domain. PARP
activity, poly(ADP-ribosyl)ation or PARsylation of
acceptor proteins, is emerging as an important regu-
latory mechanism in the cell and is gaining increas-
ing attention in the scientific literature. The most
studied function of PARP enzymes is their function
in the DNA repair machinery (PARP-1 and PARP-2);
however, PARPs are involved in many biological
processes, and specific functions are yet to be as-
signed to several members of the family.3 In addition
to the PARP domain [residues 1091–1313; National
Center for Biotechnology Information (NCBI) ID
NP_003738.2], TNKS-1 carries an ankyrin repeat do-
main (residues 208–945) that facilitates binding to
TRF1 and other interaction partners,4 a sterile alpha
motif domain (residues 1028–1087) that is required
for homo- and hetero-oligomerization,5,6 and an N-
terminal HPS domain consisting of homopolymeric
tracts of His, Pro and Ser (Fig. 1).1d.
Fig. 1. Structure of the catalytic domain of TNKS-1. (a) Stereo view of the catalytic domain. Residues that are not
conserved between TNKS-1 and TNKS-2 are colored red. The Zn ion is shown as a sphere. The disordered loop 1283–1286
is shown as a dashed line. The donor and acceptor NAD+ binding sites are labeled as well as secondary-structure elements
and N- and C-termini. Amino acid difference between the reported structure in comparison with NP_003738 (NCBI ID),
M1266I, is colored black. (b) Sequence alignment of the TNKS-1 and TNKS-2 PARP domains and structural alignment with
humanPARP-1. Identical residues are uncolored, similar are colored blue andunconserved in red. The residues binding the
zinc ion are highlighted in magenta and the PARP signature sequence (HYE) is shaded grey in all sequences. All the
residues interacting with NAD in the PARP-1 model2 are marked with a *. B-, D- and G-loops referred to in the text are
labeled (sequence of PARP-1 B-loop is not shown). Residues used in the alignment are in gray-shaded capital letters.
Residues of PARP-1, whichwere not aligned, are in small letters. M1266I change is in bold letters. The secondary structural
elements are labeled as in (a). The numbering corresponds to TNKS-1 sequence.
137PARP Domain of Tankyrase 1TNKS-1 localizes to many sites within the cell such
as telomeres, spindle poles and cytoplasmic mem-
brane compartments.4 Its catalytic activity has been
shown to be required also for progression through
mitosis.7,8 However, the most documented function
of TNKS-1 is its involvement in telomere homeos-
tasis.1,4 Human telomerase is a reverse transcriptase
that maintains telomere length by adding telomeric
repeats to the ends of chromosomes.9 Telomeres are
protected by a nucleoprotein complex referred to as
the shelterin complex (de Lange10 and references
therein). PARsylation of TRF1 by TNKS-1 disrupts
the shelterin complex and exposes the telomeric
DNA. Telomerase can then access the DNA and add
telomeric repeats. In normal cells, where progressive
telomere shortening limits the number of cell
divisions before cells reach replicative senescence,
telomerase activity cannot be detected or is verylow.11 On the other hand, telomerase activity is high
in germ cells and several cancer cells.12–15 Inhibition
of telomerase activity provides an exciting opportu-
nity for development of novel cancer therapies and
has been a field of intense study over the last 10
years.16 As a positive regulator of telomerase, TNKS-
1 is an attractive target for drug development, and
inhibition of the TNKS-1 PARP activity has been
demonstrated to work synergistically with direct
telomerase inhibition to enhance telomere shorte-
ning.17 Several small−molecule PARP inhibitors are
available and at least six clinical trials with selective
PARP-1 inhibitors for the treatment of various onco-
logy conditions are ongoing or due to be started.18
This shows great promise for the future development
of tankyrase inhibitors.
Here we report the crystal structure of the PARP-
domain of TNKS-1, which represents the first
138 PARP Domain of Tankyrase 1structure of a tankyrase from any species. The
catalytic domain of TNKS-1 is structurally homo-
logous to the PARP-proteins reported earlier, but the
structure displays distinct features of potential
biological and pharmaceutical importance. In parti-
cular, the donor NAD+ binding site of TNKS-1 is not
conserved in other members of the PARP family,
which will be of importance for the development of
selective tankyrase inhibitors. The structure also
reveals that TNKS-1 contains a zinc-binding motif
that has not been reported or predicted before. The
short zinc-bindingmotif may be involved in protein–
protein and/or protein–DNA interactions and thus
in the activation of the PARP-reaction catalyzed by
tankyrases.Results and Discussion
Overall structure
The structure of the PARP domain of human
TNKS-1 comprises residues 1104–1314 and consists
of two central β-sheets consisting of five (β1, β2, β3,
β5 and β9) and four strands (β4, β6, β7 and β8) (Fig.
1a). The core β-sheets are surrounded by four α-
helices and loops. A small loop (1283–1286) was not
built as the electron density for that region was
completely missing. Overall, the TNKS-1 PARP
domain structure is similar to the previously
reported crystal structures of PARP-enzymes.2,19 In
comparison with PARP-1,20 the principal secondary
structure features (nine β-strands and four α-
helices) of TNKS-1 are conserved (Fig. 1b). One of
the helices, α2, is longer in TNKS-1 than in PARP-1.
The region surrounding the PARP catalytic core,
however, shows significant variability (Fig. 2a). The
most striking feature, already known based on the
sequence, is that the N-terminal α-helical domain of
PARP-1 is completely missing in TNKS-1. This
domain is thought to modulate the activity of
DNA-dependent PARPs.2,22 Another large deletion
in comparison with PARP-1 is on the backside of the
catalytic domain where a 32-amino-acid loop (952–
984, B-loop) (Fig. 2a) is replaced by a small loop in
which four residues were disordered in the present
crystal structure. Loops at the analogous position
are thought to participate in substrate specificity of
mono(ADP-ribosyl)ating toxins.23
Despite the conservation of secondary-structure
elements, there are large differences in the loop struc-
tures, which are of potential functional importance.
Most interestingly, the TNKS-1 catalytic domain has a
short zinc-binding motif, which is present only in
tankyrases and not in other member of the PARP-
family (see below).
Lastly, TNKS-1 and TNKS-2 are very similar in
domain organization as well as in sequence. For the
catalytic domain presented here the sequence identity
between TNKS-1 and TNKS-2 is 89% (Fig. 1b).
Mapping the variable residues onto the TNKS-1
structure (Fig. 1a) shows that all differences are loca-ted far away from the active site, as expected for
enzymes catalyzing the same reaction with the same
substrate proteins.
Active site, implications for inhibitor design
The PARP catalytic domain contains two distinct
binding sites referred to as the donor and acceptor
sites (Fig. 1a). In the initiation reaction, when NAD+
is first added to a glutamate of a target protein, NAD+
occupies the donor site. This donor site has been
mapped based on the similarity with mono(ADP-
ribosyl)ating toxins.2 During the initiation reaction
the target protein must occupy the acceptor site in
order to position itself for the reaction. In the elonga-
tion reaction the donor site is occupied by NAD+ and
the acceptor site is occupied by the growing poly
(ADP-ribose) (PAR) chain. The only structural evi-
dence for the acceptor site so far has been the observ-
ation of a poorly defined fragment of a NAD+ analog
in a crystal structure of PARP-1.24 The “catalytic
triad” of PARPs is defined by an HYE motif near the
donor nicotinamide binding site (NI subsite), al-
though this motif is not completely conserved within
the family.25 The triad His1184-Tyr1213-Glu1291 is,
however, conserved in tankyrases as is the rest of the
NI subsite.
All of the current PARP inhibitors, at least those for
which structural information is available, mimic the
NImotif and thus target the NI subsite, with different
extensions towards the rest of the donor site.20,21,26
This mode of interaction is confirmed in all PARP-1
complex structures published to date. The main in-
teractions that are shared between NAD+ and PARP
inhibitors are stacking between two tyrosine residues
(Tyr1213 and 1224) and hydrogen bonds with the
backbone carbonyl and amide of Gly1185 and side
chain of Ser1221. Many attempts to identify novel
PARP-1 inhibitors have been made and the patent
literature is abundant.27,28
In the following we compare the TNKS-1 structure
with two representative PARP-1 structures in complex
with inhibitors, for which we generated improved
structural models based on the existing experimental
data (see Materials and Methods). It is apparent that
the features that are key for inhibitor binding to the NI
subsite are conserved also in TNKS-1 (Fig. 1b). How-
ever, the regions lining the adenosine (AD) subsite of
the donor site are different in TNKS-1 and PARP-1
and may thus provide a route for design of selective
inhibitors. In particular, the D-loop F1197–G1211 has
low sequence conservation and displays a different
conformation in TNKS-1. This loop adopts an open
conformation in all PARP-1 structures, whereas it
adopts a closed conformation in the TNKS-1 structure
(Fig. 2b). In fact, the inhibitors visible in the PARP-1
structures20,21 sterically clash with the TNKS-1 D-loop
when overlaid (Fig. 2b). The TNKS-1 D-loop has
higher temperature factors than the protein on ave-
rage and is thus likely to be flexible. We propose that
upon NAD+ or inhibitor binding this loop may adopt
a conformation similar to that of the PARP-1 apo
structure. However, due to its low sequence
Fig. 2. Comparison of TNKS-1 and PARP-1. (a) Superposed humanTNKS-1 and PARP-1 (re-refined 1UK1;seeMaterials
and Methods). Aligned residues are also shown in Fig. 1b. The catalytic glutamate (1291) is shown as sticks as are the
residues of PARP-1 N-terminal domain that are suggested to participate in NAD+ binding.2 The zinc ion is shown as a
sphere. The helices of TNKS-1 are labeled as in Fig. 1a. Inhibitors bound to the PARP-1 structures are shown as sticks: 5-
fluoro-1-[4-(4-phenyl-3,6-dihydropyridin-1(2H)-yl)butyl]quinazoline-2,4(1H,3H)-dione in 1UK1 (orange)20 and FR257517
in 1UK0 (grey).21 The donor-site loop,which changes conformation uponNAD+ binding (D-loop), a loopmissing in TNKS-
1 but present in PARP-1 (B-loop) and the glycine-rich loop (G-loop) are labeled. (b) Closed donor site. Surface of PARP-1
(1UK1) is shown in orange as in (a), but it was calculated without the N-terminal domain. TNKS-1 is shown in blue to
emphasize the almost complete closure of this binding site in TNKS-1. Subsites for NAD+ binding are labeled: NI,
nicotinamide-binding site; PH, phosphate-binding site; AD, adenosine-binding site. The AD site is partly occupied by a
glycerol molecule in TNKS1. Inhibitors are shown as in (a). Residues closing the donor site in TNKS1 are shown as sticks
and labeled, as are the structural features lining the donor site (B-loop, D-loop and α3).
139PARP Domain of Tankyrase 1conservation, the interactions with the adenosine part
of NAD+, or inhibitors binding in this site, cannot be
fully conserved. Interestingly, a loop at this region is
thought to control the substrate specificity of mono-
ribosylating toxins.23 It is also noteworthy that the
similar active-site loop gets disordered or changes
conformation in diphtheria toxin and in Pseudomonasexotoxin A upon NAD+ binding.29,30 Moreover, the
helix α3 provides a base for the AD subsite via interac-
tions with its main-chain atoms.24 This helix is slightly
shorter in TNKS-1 due to the insertion of a proline
(Pro1187) and deletion of a two-amino-acid residue,
causing movement of the helix and the preceding
loop, which results in a narrower binding pocket (Fig.
140 PARP Domain of Tankyrase 12b). In a similar manner as for the D-loop, steric
clashes are observed when the PARP-1 inhibitor com-
plex [Protein Data Bank (PDB) code 1UK0] is super-
posed with the TNKS-1 structure (Fig. 2b). Although
the structure must change upon NAD+ or inhibitor
binding, the steric clash between Phe1188 and the
inhibitor is striking and thus inhibitors designed for
PARP-1 and binding to this sitemay not inhibit TNKS-
1. The same clashes described above are observed also
using the original published coordinates of 1UK0 and
1UK1 (Supplementary Fig. 1). It should also be noted
that the movement of the glycine-rich loop (G-loop;
Fig. 2) following α4 also results in a slightly narrower
NI site that could also potentially affect binding of NI
mimics. The G-loop also connects the zinc-binding
motif to the active site of TNKS-1 (see below).
Taken together, these observations point to oppor-
tunities for the design of selective TNKS inhibitors.
The conserved interactions in the NI site provide an
anchor, and it should be possible to base the develop-
ment of future TNKS inhibitors on the many binding
scaffolds identified for PARP-1. In fact,many PARP-1
inhibitors have been used to inhibit also TNKS-1.17
By extending existing scaffolds by novel substitu-
tions probing the AD subsite, it should be possible to
find unique interactions with non-conserved D-loop
residues in particular. This situation is very much
analogous to what is observed for protein kinase
inhibitors; for example, a number of highly con-
served interactions are shared by many inhibitors,
yet it is possible to identify reasonably selective
compounds by proper substitutions.31
Zinc-binding motif
Surprisingly, the loop formed by residues 1224–
1247 contains a novel, not previously predicted zinc-
finger-like motif. According to the sequence align-
ment, the zinc-bindingmotif is unique to TNKS-1 and
TNKS-2 and is not present in any other PARP
enzyme.25 The presence of zinc in the metal-binding
site was suggested by the tetrahedral coordination by
mainly cysteines, typical for zinc ions,32,33 and was
confirmed byX-ray fluorescence emission spectra and
energy absorption spectra (data not shown). The zinc
ion is coordinated by three cysteines (Cys1234,
Cys1242 and Cys1245) and one histidine (His1237)
(Figs. 1b and 3a). The loop of four residues between
the zinc-binding residues (His1237 and C1242) turns
back towards the protein (Fig. 3a). Two hydrophobic
residues (Tyr1243 and Ile1244) between the last two
cysteines (Cys1242 and Cy1245) attach the loop
structure to the main body of the protein. Between
TNKS-1 and TNKS-2 there is only one amino acid
substitution in the Zn-binding loop sequence:
Thr1236 is a valine in TNKS-2 (Fig. 1). The Thr1236
side chain is on the outer side of the loop pointing
towards the solvent (Fig. 3a) and thus this change
should not affect the conformation of the loop or zinc
binding. The zinc atom inTNKS-1 is located 33Å from
the catalytic Glu1291, making it very unlikely that it
participates directly in catalysis (Fig. 1a). It is also 20Å
away from the closest parts of the donor NAD+binding site. This indicates that the zinc-bindingmotif
may be a structural element needed for protein
stability or it may have a regulatory function.
A SPASM search35,36 to find structuralmotifs in the
PDB similar to the loop Cys1234–Cys1245 did not
identify any homologous motifs, but when only the
Zn-coordinating residues were used, SPASM found
nine similar unique entries in the PDB. All entries
contain a zinc ion, and although the coordinating
residues are at similar positions, only structures of
RING-type zinc fingers display the same order of
coordinating residues. Ring fingers are not structu-
rally related to the zinc finger in TNKS-1, as the
connecting loop in the RING fingers is significantly
longer37—between 17 and 22 residues in the hits
found by SPASM. Interestingly, the SPASM search
identified motifs differing in sequence, but of a
length similar to that found in TNKS-1. These short
motifs can be grouped into the class of “short zinc-
binding motifs”.38 In the short zinc-binding motifs,
at least three of the four zinc-coordinating residues
belong to the same short loop. According to Krishna
et al., this group comprises 12 motifs belonging to
two families composed of sequences where all four
Cys/His residues are found in the same loop (family
I) and motifs where one of the coordinating residues
is separated in the primary amino acid sequence
(family II).38 The TNKS-1 zinc-binding loop clearly
belongs to family I of short zinc-binding loops as the
whole motif consists of only 12 residues. Family I con-
sists of nucleotide interacting proteins (1CYQ, 1I3Q,
1A5Tand 1GPC) and metabolic enzymes (1HSO and
1E3J). Notably, none of the identified short zinc-bin-
ding loops appear to be catalytically important, but
are involved in forming protein–protein interact-
ions39–43 or have a purely structural role in stabiliz-
ing the protein fold.44
Biological function of the zinc-binding motif
Based on a BLAST search, the zinc-binding motif is
conservedamongspecies except inone isoformofMus
musculusTNKS-1 (EDL35447),where the zinc-binding
loop is completely deleted. Although this gene
sequence might be just an error in sequencing, it is
interesting that TNKS-1 is suggested not to interact
with TRF1 in M. musculus.45 Due to its conservation
among species it appears that the zinc-bindingmotif is
of functional importance. Although the zinc ion
is located far away from the active site, it is connected
to the donor site via the G-loop, and it couldmodulate
the activity through this protein backbone link.
Many of the classic zinc fingers function through
DNA binding and contain a highly basic/polar area
that participates in binding to the DNA backbone.46
The electrostatic potential of the TNKS-1 zinc-binding
motif is positive (Fig. 3b), indicating that it could
interact with a negatively charged partner, such as
nucleic acids. Although DNA has been reported to
increase TNKS-1 activity in some experiments,47 the
authors concluded that DNA would not modulate
the activity of TNKS-1 because this was not seen re-
producibly. Indeed it is not known what signal, or
Fig. 3. The zinc-binding motif in TNKS-1 (a) The loop containing the zinc-binding residues is shown. The zinc ion
(magenta) and the twowater molecules (red) closest to the zinc ion are shown as spheres. Hydrogen bonds to zinc andwater
molecules by the side chains are drawnas dashed lines. Distances are in angstroms. The anomalousmap is contoured in green
at 4σ (0.10 e/Å3). Themolecular surface of TNKS-1, excluding the zinc loop, is shown in light blue. The figurewasmadewith
Pymol.34 (b) The electrostatic surface ofTNKS-1.Colour codingof themolecular surface goes from red (−5 kcal/e.u. charge) to
blue (+5 kcal/e.u. charge). Zn2+was included in the calculations and the zinc-binding loop is labeledwith “Zn”. Carba-NAD
in PARP-1 (1A26) is shown as a stick model to indicate the acceptor site. Two views of the molecule, 90° apart, are shown.
141PARP Domain of Tankyrase 1signals, trigger the TNKS-1 activity; however, a zinc-
binding motif could act as a platform for interaction
with DNA or an acidic protein molecule. The positive
charge around the zinc-binding motif is typical for
DNA-binding zinc fingers and thus it should not yet
be excluded that DNA, under some circumstances,
could activate TNKS-1. Recently zinc fingers have
been reported to function also as PAR-binding mo-
tifs48; this would be a possible and interesting func-
tion for the zinc-binding motif of tankyrases.
Concluding remarks
The analysis of the TNKS-1 structure in light of the
existing structural knowledge of other PARP en-
zymes and PARP inhibitors shows that there is
clearly potential for the development of selectiveTNKS-1 inhibitors. By making proper substitutions
on existing or novel scaffolds targeting the PARP NI
site, it should be possible to identify compounds that
have specific interactions, in particular with the non-
conserved D-loop. Although we cannot present a
clear function for the zinc-binding motif of TNKS-1,
it is tempting to propose that it could form a platform
for interactionswith some of the protein components
of the shelterin complex, e.g., by providing a binding
site for TIN2, which is known to stabilize the TNKS-
1–TRF1 complex and prevent PARsylation of
TRF1.49 TRF1 binds to the C-terminal subdomain
of the ankyrin domain of TNKS-1 being separated by
a sterile alpha motif domain from the PARP-do-
main50; thus, TIN2 could participate in this interplay
of the domains by modulating the activity in a simi-
lar fashion as the helical domain of PARP-1.
Table 1. Data and refinement statistics
Data statistics
Wavelength (Å) 0.97981
Space group I212121
Cell dimensions
a (Å) 79.95
b (Å) 81.24
c (Å) 82.72
Resolution (Å) 20–2.3
(2.4–2.3)
Rmerge
c 16.6 (47.0)
142 PARP Domain of Tankyrase 1Materials and Methods
Cloning and protein expression
The TNKS-1 gene clone was obtained from National
Institutes of Health Mammalian Gene Collection (MGC),
accession no. BC098394. The sequence encoding residues
1091–1325 was amplified by PCR and inserted into
pNIC28-Bsa4 vector by ligation-independent cloning.
The MGC clone contains an amino acid difference (in
comparison with NCBI sequence NP_003738), M1266I,
which is located on the surface of the protein (Fig. 1a). The
construct included an N-terminal tag containing 6-His
sequence (MHHHHHHSSGVDLGTENLYFQSM). For ex-
pression, the pNIC-Bsa4 containing the insert was trans-
formed into Escherichia coliRosetta2(DE3) strain and stored
at −80 °C.
Cells from the glycerol stock were streaked on an LB
agar plate supplemented with 50 μg/ml kanamycin and
34 μg/ml chloramphenicol and incubated overnight at
37 °C. Several colonies from the plate were used to inocu-
late 20 ml of Terrific Broth supplemented with 8 g/l glyce-
rol, 100 μg/ml kanamycin and 34 μg/ml chloramphenicol
and grown at 30 °C overnight. The 20-ml culture was used
to inoculate 1.5 l Terrific Broth media supplemented with
8 g/l glycerol, 50 μg/ml kanamycin, 34 μg/ml chloram-
phenicol and 5 drops of BREOX (anti-foaming agent) in a 2-
l glass flask. Cells were grown in a Large-Scale Expression
System at 37 °C until the OD600 reached 2. The cultivation
was down-tempered to 18 °C for 1 h. Expression of TNKS-1
was induced by the addition of 0.5 mM IPTG and conti-
nued overnight at 18 °C. Cells were harvested by centrifu-
gation at 5500g for 10 min at 4 °C. The pellet was resus-
pended in lysis buffer containing 50 mM Hepes (pH 7.5),
300 mM NaCl, 10% glycerol, 10 mM imidazole, 0.5 mM
tris(2-carboxyethyl)phosphine (TCEP) and complete ethy-
lenediaminetetraacetic-acid-free protease inhibitor (Roche
Biosciences). Resuspended cells were stored at −80 °C.I/σ(I) 13.4 (4.2)
Completeness (%) 97.8 (99.9)
Redundancy 9.0 (7.5)
Unique reflections 12043
Refinement statistics
Rwork
a/Rfree
b 0.193/0.250
No. atoms 1767
Protein 1664
Water 96
Zinc 1
Glycerol 6
B-factors (Å2)
Protein 24.1
Zinc 27.3
Other 26.9
RMSDs
Bond lengths (Å) 0.013
Bond angles (°) 1.336
Ramachandran plot (%)d
Favoured 97.5
Additionally allowed 2.5
Values for the highest resolution shell are shown in parentheses.
a Rwork is defined as ∑∣∣Fobs∣−∣Fcalc∣∣/∑∣Fobs∣, where Fobs
and Fcalc are observed and calculated structure-factor amplitudes,
respectively.
b Rfree is the R−factor for the test set (8% of the data, 968
reflections).
c Rmerge=∑i∣Ii− 〈I〉∣/∑〈I〉, where I is an individual intensity
measurement and 〈I〉 is the average intensity for this reflection
with summation over all data.
d According to Molprobity.51Protein purification
The frozen cell suspension was thawed and 4 μl of 250
U/μl benzonase (Novagen) was added per 50 ml of sus-
pension. The sample was sonicated on ice (Sonics Vibra-
Cell) at 80% amplitude, 4 s on, 4 s off, for 3 min followed
by centrifugation at 49,000g for 20 min at 4 °C. The soluble
fraction was decanted and filtered through a 0.45-μm
filter.
Purificationwas conducted automatically on anÄKTAx-
press system (GE Healthcare) operated by UNICORN.
Prior to purification, a 1-ml HiTrap chelating column was
equilibrated with buffer 1 (30 mM Hepes, 500 mM NaCl,
10% glycerol, 10 mM imidazole, pH 7.5, 0.5 mM TCEP). A
Superdex 75 gel filtration column (HiLoad 16/60, GE
Healthcare) was equilibrated with buffer 2 (30 mMHepes,
300 mM NaCl, 10% glycerol, pH 7.5, 0.5 mM TCEP). The
cleared lysate was loaded onto the HiTrap chelating co-
lumn and the column was washed with buffer 1 followed
by awashwith the same buffer supplemented with 25mM
imidazole. Bound protein was eluted from the IMAC
columns with buffer 1 containing 500 mM imidazole and
loaded onto the gel filtration column run using buffer 2.
The UV280 absorption chromatogram of the eluate showed
one major protein peak at a retention volume of 65 ml, in-
dicating monomeric protein. This peak consisted of TNKS-
1 as analyzed by SDS-PAGE and routine electrospray ioni-
zation mass spectrometry. Fresh TCEP was added to thepooled protein peak to a final concentration of 2 mM and
the proteinwas concentrated to 22.8mg/ml (0.28ml) using
an Amicon Ultra 15 (Millipore) centrifugal concentrator
with a 10,000 molecular weight cutoff. The preparation
was flash-frozen in small aliquots for storage at −80 °C.
Crystallization, data collection and structure
determination
TNKS-1 crystals were grown by sitting-drop vapour
diffusion. Protein (18.2 mg/ml; 0.2 μl) was mixed with
reservoir solution (0.1 μl) containing 18% polyethylene
glycol 3350, 180 mMmagnesium formate (pH 5.9) and 3%
1,6-hexanediol. The dropwas equilibrated at 20 °C over the
precipitant solution and rodlike crystals appeared in 3
days.
A crystal was picked upwith a nylon loop, dipped into a
cryosolution (precipitant solution supplemented with 20%
glycerol and 300 mM NaCl) and frozen in liquid nitrogen.
Data to 2.3 Å resolution were collected at beamline 14.1
(Bessy, Berlin). As data contained intense ice rings, a lower
resolution data (2.6 Å) from identically grown crystals
were also collected. Resolution shells of the ice rings were
excluded from the higher resolution data and the two data
sets were scaled together (Table 1). Data were processed
with XDS52 in space group I212121 (a=79.95 Å, b=81.24 Å
143PARP Domain of Tankyrase 1and c= 82.72 Å). The structure was solved with
MOLREP53,54 using PARP-12 (PDB code 2PQF) with trun-
cated side chains as a search model. Model building was
done with COOT55 and refinement with REFMAC5 (Table
1).56 TLS refinement with three groups was carried out in
REFMAC5 with the groups selected according to the sug-
gestion of the TLS motion determination server.57,58
Re-refinement of human PARP-1 structures
In order to compare differences between human TNKS-1
and PARP-1, the low-resolution (3 Å) models of human
PARP-1 (PDB codes 1UK0,21 1UK120 and 1WOK26) were
analyzed using the Molprobity server.51 It was evident that
the geometry of these structural models could be improved,
and these structures were therefore first refined against the
original diffraction data obtained from the PDB. For 1UK1
and 1UK0, a new test set was created and bias was re-
moved by removing solvent atoms, resetting B-factors and
running molecular replacement with MOLREP.53,54 In the
first refinement cycles, simulated annealing was used with-
in PHENIX59 and later refinement cycles were done with
REFMAC5.56 One TLS group per monomer was used with
1UK0 and 1UK1, and for 1WOK the N-terminal helical do-
main and the PARP domain were defined as separate TLS
groups. The re-refinement of the 1UK0 and 1UK1 PARP-1
inhibitor complexes resulted in improved models, as
judged by Molprobity.51 Molprobity scores for the three
structures improved from 3.7–4.2 to 2.1–2.5 and the fraction
of residues in favoured regions of the Ramachandran plot
from 70.5–82.5% to 96.3–97.8%. The improved structures
were used in the further analysis. It should also be pointed
out that the observed electron density for the inhibitor in
1WOK is poor‡.
Analysis of the structure and alignments
The alignment of TNKS-1 and TNKS-2 was carried out
using ClustalW.60 Structural alignments were done with
COOT55 using the secondary-structure matching based
algorithm.61 The anomalous map (Fig. 3a) was calculated
from data scaled without merging the Friedel pairs and
using the model coordinates as phase information. All the
figures excluding Fig. 3b were generated with Pymol.34
The electrostatic surface shown in Fig. 3b was calculated
using ICM (Molsoft).
Protein Data Bank accession codes
The coordinates and structure factors of TNKS-1 were
deposited at the PDB under accession code 2RF5.Acknowledgements
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